Cyclacel Pharmaceuticals, Inc. (CYCC.W)
2.22USD
8 Feb 2010
$-0.20 (-8.70%)
$2.22
--
$2.35
$2.07
2,399,470
4,127,515
$4.08
$0.25
CYCC.W
About
Overall
| Beta: | 2.19 |
| Market Cap (Mil.): | $60.81 |
| Shares Outstanding (Mil.): | 28.96 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| CYCC.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 48.05 | -- | -- |
| ROI: | -115.98 | 1.25 | 2.30 |
| ROE: | -122.89 | 2.09 | 2.82 |
Cyclacel shares extend gains on lung cancer drug data
(Reuters) - Shares of Cyclacel Pharmaceuticals were up for the second day, after two peer-reviewed journal articles found its drug candidate, seliciclib, effective against lung cancer.
US-RESEARCH/ (NON-S&P500)
Hewitt Associates Goldman Sachs Removes from Americas conviction sell list --------------------------------------------------------------- ------------ Intersil Corp JP Morgan Cuts to neutral from overweight --------------------------------------------------------------- ------------ Itron Inc JP Morgan Cuts to neutral from overweight --------------------------------------------------
HEADLINE STOCKS-Some U.S. stocks on the move on Jan 6
NEW YORK, Jan 6 (Reuters) - Some U.S. stocks on the move on Tuesday:
HEADLINE STOCKS-Some U.S. stocks to watch on Jan 6
NEW YORK, Jan 6 (Reuters) - Some U.S. stocks to watch on Tuesday:
UPDATE 1-Susquehanna starts 10 biotech cos with positive
Oct 21 (Reuters) - Susquehanna Financial Group began coverage of 10 biotechnology firms with a "positive" rating, and said the companies offered strong development capabilities and broad commercial potential in oncology and inflammation.
UPDATE 1-Cyclacel to cut 28 jobs, take Q3 charge
Sept 16 (Reuters) - Cyclacel Pharmaceuticals Inc said it will cut about 28 jobs, or 34 percent of its workforce, close a UK research facility and take a $0.5 million charge to focus on the development of its lead cancer drug sapacitabine.
US RESEARCH NEWS-Bernstein cuts Fifth Third Bancorp target
Following are the research actions reported by Reuters on Tuesday. --------------------------------------------------------------- ------------ STOCK RESEARCH BY ACTION Fifth Third Bancorp Bernstein Cuts price target to $29 from $33; keeps market perform rating --------------------------------------------------------------- ------------ Capital One Financial Bernstein Cuts price target to $81 from $8
Cyclacel Pharmaceuticals Q3 results
CYCLACEL PHARMACEUTICALS INC : * Third quarter per share loss $0.21 * Reuters Estimates third quarter earnings per share view $-0.37
UPDATE 3-Deals of the day -- mergers and acquisitions
Oct 8 (Reuters) - The following bids, mergers, acquisitions and disposals involving European, U.S. and Asian companies were reported by 2000 GMT on Monday.
Cyclacel Pharma acquires Align
Oct 8 (Reuters) - Cyclacel Pharmaceuticals Inc said it agreed to acquire all assets of privately-held Align Pharmaceuticals and Align Holdings for about $3.3 million to $3.8 million in cash.
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Genzyme Corporation (GENZ.OQ) | $54.87 | +0.38 |
| GlaxoSmithKline plc (GSK.L) | £1,201.50 | -17.00 |
| AstraZeneca plc (AZN.L) | £2,812.50 | -3.00 |
| Eisai Co., Ltd (4523.T) | ¥3,285.00 | -15.00 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| Piramal Life Sciences Limited (PLSL.BO) | Rs79.35 | +0.10 |
| Roche Holding Ltd. (ROG.VX) | CHF175.90 | -0.20 |
| Sunesis Pharmaceuticals, Inc. (SNSS.OQ) | $0.81 | -0.03 |
| Sanofi-Aventis SA (SASY.PA) | €53.01 | +0.35 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
